TCG
ABBV icon

Transcendent Capital Group’s AbbVie ABBV Stock Holding History

Transcendent Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-292
Closed -$51.9K – 89
2024
Q4 		$51.9K Sell
292
-38
-12% -$6.99K 0.03% 183
2024
Q3 		$65.2K Sell
330
-4
-1% -$747 0.03% 186
2024
Q2 		$57.3K Buy
334
+4
+1% +$663 0.03% 176
2024
Q1 		$60.1K Hold
330
– – 0.03% 173
2023
Q4 		$51.1K Buy
+330
New +$48.1K 0.03% 148

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Transcendent Capital Group's ABBV Position: Q1 2025 in Review

Transcendent Capital Group sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 292 shares — an estimated $51.9K sold.

Transcendent Capital Group first reported a position in ABBV in Q4 2023 and held it in 5 quarters. The position peaked at $65.2K in Q3 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Transcendent Capital Group reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
  • Transcendent Capital Group sold 292 AbbVie shares in Q1 2025, an estimated $51.9K.
  • Transcendent Capital Group first reported a position in AbbVie in Q4 2023 and held it in 5 quarters.
  • Transcendent Capital Group's AbbVie position peaked at $65.2K in Q3 2024.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Transcendent Capital Group's 13F filing for Q1 2025, filed 2 May 2025.